European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
European Approval Based on KEYNOTE-407 Study Results Demonstrating
Significant Improvement in Overall Survival with KEYTRUDA in Combination
with Chemotherapy Compared to Chemotherapy Alone
KEYTRUDA is First Anti-PD-…